Oral L-carnitine supplementation increases trimethylamine-N-oxide but reduces markers of vascular injury in hemodialysis patients

Journal of Cardiovascular Pharmacology

Volumn 65, Issue 3, 2015, Pages 289-295

  Fukami, Kei ^a   Yamagishi, Sho Ichi ^a   Sakai, Kazuko ^a   Kaida, Yusuke ^a   Yokoro, Miyuki ^a   Ueda, Seiji ^a   Wada, Yoshifumi ^b   Takeuchi, Masayoshi ^c   Shimizu, Makiko ^d   Yamazaki, Hiroshi ^d   Okuda, Seiya ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Wada Cardiovascular Clinic   (Japan)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

^d SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

atherosclerosis; hemodialysis; L carnitine; TMA; TMAO

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CARNITINE; INTERCELLULAR ADHESION MOLECULE 1; MALONALDEHYDE; MARKER; TRIMETHYLAMINE; TRIMETHYLAMINE OXIDE; VASCULAR CELL ADHESION MOLECULE 1; BIOLOGICAL MARKER; ICAM1 PROTEIN, HUMAN; METHYLAMINE; TRIMETHYLOXAMINE;

ADULT; ARTICLE; BLOOD VESSEL INJURY; CARNITINE DEFICIENCY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; SUPPLEMENTATION; ADVERSE EFFECTS; AGED; BLOOD; CASE CONTROL STUDY; COMPLICATION; DEFICIENCY; DEFICIENCY DISEASES; DIET SUPPLEMENTATION; DRUG EFFECTS; JAPAN; KIDNEY DISEASES; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RENAL REPLACEMENT THERAPY; TIME; TREATMENT OUTCOME; VASCULAR SYSTEM INJURIES;

ADMINISTRATION, ORAL; AGED; BIOMARKERS; CARNITINE; CASE-CONTROL STUDIES; DEFICIENCY DISEASES; DIETARY SUPPLEMENTS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; JAPAN; KIDNEY DISEASES; MALE; MALONDIALDEHYDE; METHYLAMINES; MIDDLE AGED; OXIDATIVE STRESS; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME; VASCULAR CELL ADHESION MOLECULE-1; VASCULAR SYSTEM INJURIES;

EID: 84925519643     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000197     Document Type: Article

References (34)

1. Zhang AQ, Mitchell SC, Smith RL. Dietary precursors of trimethylamine in man: a pilot study. Food Chem Toxicol. 1999;37:515-520.
2. Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368: 1575-1584.
3. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472:57-63.
4. Suzuki H, Kurihara Y, Takeya M, et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature. 1997; 386:292-296.
5. Evans AM, Fornasini G. Pharmacokinetics of L-carnitine. Clin Pharmacokinet. 2003;42:941-967.
6. Adachi T, Fukami K, Yamagishi S, et al. Decreased serum carnitine is independently correlated with increased tissue accumulation levels of advanced glycation end products in haemodialysis patients. Nephrology (Carlton). 2012;17:689-694.
7. Carvajal K, Moreno-Sánchez R. Heart metabolic disturbances in cardiovascular diseases. Arch Med Res. 2003;34:89-99.
8. Ascunce RR, Nayar AC, Phoon CK, et al. Cardiac magnetic resonance findings in a case of carnitine deficiency. Tex Heart Inst J. 2013;40:104-105.
9. Fukami K, Yamagishi S, Sakai K, et al. Potential inhibitory effects of Lcarnitine supplementation on tissue advanced glycation end products in patients with hemodialysis. Rejuvenation Res. 2013;16:460-466.
10. Yamagishi S. Potential clinical utility of advanced glycation end product cross-link breakers in age-and diabetes-associated disorders. Rejuvenation Res. 2012;15:564-572.
11. Takahashi M, Ueda S, Misaki H, et al. Carnitine determination by an enzymatic cycling method with carnitine dehydrogenase. Clin Chem. 1994;40:817-821.
12. Shimizu M, Kozono M, Murayama N, et al. Bonitos with low content of malodorous trimethylamine as palliative care for self-reported Japanese trimethylaminuria subjects. Drug Metab Pharmacokinet. 2009;24:549-552.
13. Yamazaki H, Fujieda M, Togashi M, et al. Effects of the dietary supplements, activated charcoal and copper chlorophyllin, on urinary excretion of trimethylamine in Japanese trimethylaminuria patients. Life Sci. 2004; 74:2739-2747.
14. Yamagishi S, Matsui T, Nakamura K, et al. Pigment epithelium-derived factor (PEDF) prevents diabetes-or advanced glycation end products (AGE)-elicited retinal leukostasis. Microvasc Res. 2006;72:86-90.
15. Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19:576-585.
16. Yamagishi S, Matsui T, Nakamura K, et al. Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species. Ophthalmic Res. 2008;40:10-15.
17. Ishibashi Y, Matsui T, Maeda S, et al. Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc Diabetol. 2013;12:125.
18. Matsui T, Nishino Y, Takeuchi M, et al. Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis. Pharmacol Res. 2011;63:383-388.
19. Lawson C, Wolf S. ICAM-1 signaling in endothelial cells. Pharmacol Rep. 2009;61:22-32.
20. Preiss DJ, Sattar N. Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis? Int J Clin Pract. 2007;61:697-701.
21. Nakashima Y, Raines EW, Plump AS, et al. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler Thromb Vasc Biol. 1998;18: 842-851.
22. Poston RN, Haskard DO, Coucher JR, et al. Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am J Pathol. 1992;140: 665-673.
23. Richardson M, Hadcock SJ, DeReske M, et al. Increased expression in vivo of VCAM-1 and E-selectin by the aortic endothelium of normolipemic and hyperlipemic diabetic rabbits. Arterioscler Thromb. 1994;14: 760-769.
24. Collins RG, Velji R, Guevara NV, et al. P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice. J Exp Med. 2000; 191:189-194.
25. Bourdillon MC, Poston RN, Covacho C, et al. ICAM-1 deficiency reduces atherosclerotic lesions in double-knockout mice (ApoE(-/-)/ICAM-1(-/-)) fed a fat or a chow diet. Arterioscler Thromb Vasc Biol. 2000;20: 2630-2635.
26. Nageh MF, Sandberg ET, Marotti KR, et al. Deficiency of inflammatory cell adhesion molecules protects against atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 1997;17:1517-1520.
27. Ridker PM, Hennekens CH, Roitman-Johnson B, et al. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 1998; 351:88-92.
28. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation. 2001;103:491-495.
29. Rajasekar P, Anuradha CV. L-carnitine inhibits protein glycation in vitro and in vivo: evidence for a role in diabetic management. Acta Diabetol. 2007;44:83-90.
30. Ishibashi Y, Matsui T, Takeuchi M, et al. Beneficial effects of metformin and irbesartan on advanced glycation end products (AGEs)-RAGEinduced proximal tubular cell injury. Pharmacol Res. 2012;65:297-302.
31. DiNicolantonio JJ, Lavie CJ, Fares H, et al. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clin Proc. 2013;88:544-551.
32. de Sotomayor MA, Mingorance C, Rodriguez-Rodriguez R, et al. Lcarnitine and its propionate: improvement of endothelial function in SHR through superoxide dismutase-dependent mechanisms. Free Radic Res. 2007;41:884-891.
33. Sakai K, Fukami K, Yamagishi S, et al. Evidence for a positive association between serum carnitine and free testosterone levels in uremic men with hemodialysis. Rejuvenation Res. 2013;16:200-205.
34. Fukami K, Yamagishi SI, Sakai K, et al. Carnitine deficiency is associated with late-onset hypogonadism and depression in uremic men with hemodialysis. Aging Male. 2014;17:238-242.